Immunoprotein Diagnostic Testing Market Driven by Urgent Need for Preventive Healthcare in Emerging EconomiesNewsletter PrintingUpdated on Sep 1, 2016 View more like this | Visit ALBANY, NY | Contact Transparency market research |
Immunoproteins being a part of body’s defense mechanism, show characteristic serum concentration under abnormal conditions. Concentration of these proteins has been a prominent indicator for diagnosis of diseased state. On exposure to antigen, their levels increase 10 to 100 fold within 24 to 48 hours. These immunoproteins are thus a potential indicator for disease diagnosis. Application of these immunoproteins have shifted paradigm from microbial testing to rapid testing.
The global market for immunoprotein diagnostic testing was valued at USD 11,019.7 million in 2012 and is expected to grow at a CAGR of 5.7% from 2013 to 2019, to reach an estimated value of USD 15,351.0 million in 2019.
Chemiluminescence assay market was identified as the fastest growing segment owing to ease of use, sensitivity, and wide scope of application. The ELISA market will be fueled by introduction of multiplex ELISA technologies. On the other hand, the radioimmunoassay market is expected to decline as it is being replaced by better and safer technologies such as ELISA, chemiluminescence assay, immunofluorescence assay and others. Government restrictions on the use of radioactive substances have drastically affected the market growth. Compliance with regulatory agencies, high cost of assay equipment and safety devices have further restrained the growth of radioimmunoassay market. Immunofluorescence and immunoturbidity assay segments will be growing at a moderate CAGR of about 5% during the forecast period.
Download free exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253
C-reactive proteins (CRP) have gained considerable attention owing to their application in inflammation related disorders. CRP tests are also suggested in strokes, injuries, and cardiovascular diseases. Currently, CRP diagnostic tests are available as ELISA, chemiluminescence and immunoturbidity assay kits. Wide scope of application, excellent market penetration and availability in various technology platforms has propelled the growth of CRP diagnostic tests. Freelite assay manufactured by The Binding Site Ltd., U.K. is the only U.S. FDA approved serum free light chain (FLC) assay in the U.S. Freelite has been approved for monitoring and diagnosis of patients suffering from multiple myeloma. Currently the free light chain diagnostic test’s market is in its initial stages of development. Immunoglobulins are the most explored immunoproteins for disease diagnosis and monitoring. Owing to longstanding market position, and application in varied fields such as infectious disease testing, cancer diagnosis, allergy testing, toxicology testing and others, immunoprotein diagnostic tests market occupies largest marker share of about 30%.
Prevalence of various infectious diseases is on the rise across the globe. The scenario is alarming in developing and under developed economies where due to lack of literacy, and hygienic conditions infections spread faster. According to CDC, approximately 600,000 individuals died due to malaria in 2012 in Africa. Cancer is also a leading cause of deaths worldwide, and accounts for around 8 million deaths in 2012, according to World Health Organization. Due to these conditions, there is a demand for rapid and accurate diagnosis, which will help in diagnosis in the early stages of disease prognosis. Immunoprotein diagnostic tests have proved to be promising which have provided accurate diagnosis in least possible time. With consistent research and development activities in the field of oncology coupled with flexible assay technologies such as ELISA and CLIA, the oncology diagnostic testing segment is expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million.
The global market for immunoprotein diagnostic testing was valued at USD 11,019.7 million in 2012 and is expected to grow at a CAGR of 5.7% from 2013 to 2019, to reach an estimated value of USD 15,351.0 million in 2019.
Chemiluminescence assay market was identified as the fastest growing segment owing to ease of use, sensitivity, and wide scope of application. The ELISA market will be fueled by introduction of multiplex ELISA technologies. On the other hand, the radioimmunoassay market is expected to decline as it is being replaced by better and safer technologies such as ELISA, chemiluminescence assay, immunofluorescence assay and others. Government restrictions on the use of radioactive substances have drastically affected the market growth. Compliance with regulatory agencies, high cost of assay equipment and safety devices have further restrained the growth of radioimmunoassay market. Immunofluorescence and immunoturbidity assay segments will be growing at a moderate CAGR of about 5% during the forecast period.
Download free exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253
C-reactive proteins (CRP) have gained considerable attention owing to their application in inflammation related disorders. CRP tests are also suggested in strokes, injuries, and cardiovascular diseases. Currently, CRP diagnostic tests are available as ELISA, chemiluminescence and immunoturbidity assay kits. Wide scope of application, excellent market penetration and availability in various technology platforms has propelled the growth of CRP diagnostic tests. Freelite assay manufactured by The Binding Site Ltd., U.K. is the only U.S. FDA approved serum free light chain (FLC) assay in the U.S. Freelite has been approved for monitoring and diagnosis of patients suffering from multiple myeloma. Currently the free light chain diagnostic test’s market is in its initial stages of development. Immunoglobulins are the most explored immunoproteins for disease diagnosis and monitoring. Owing to longstanding market position, and application in varied fields such as infectious disease testing, cancer diagnosis, allergy testing, toxicology testing and others, immunoprotein diagnostic tests market occupies largest marker share of about 30%.
Prevalence of various infectious diseases is on the rise across the globe. The scenario is alarming in developing and under developed economies where due to lack of literacy, and hygienic conditions infections spread faster. According to CDC, approximately 600,000 individuals died due to malaria in 2012 in Africa. Cancer is also a leading cause of deaths worldwide, and accounts for around 8 million deaths in 2012, according to World Health Organization. Due to these conditions, there is a demand for rapid and accurate diagnosis, which will help in diagnosis in the early stages of disease prognosis. Immunoprotein diagnostic tests have proved to be promising which have provided accurate diagnosis in least possible time. With consistent research and development activities in the field of oncology coupled with flexible assay technologies such as ELISA and CLIA, the oncology diagnostic testing segment is expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million.
